The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
The Janus Rectal Cancer Trial
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU6635
U.S. Govt. ID: NCT05610163
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This study is being done to answer the following question: Can we increase the clinical complete response rate (tumor disappears by exam, endoscopy, and imaging) by adding a 3rd drug (irinotecan) to the standard chemotherapy regimens known as FOLFOX or CAPOX, given following long-course chemoradiation for patients with locally advanced rectal cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your rectal cancer. The usual approach is defined as care most people get for locally advanced rectal cancer.
Yoanna Pumpalova, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with rectal cancer? Yes No
Have you received treatment for rectal cancer? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator